Literature DB >> 15050867

Nicotine effects on brain function and functional connectivity in schizophrenia.

Leslie K Jacobsen1, D Cyril D'Souza, W Einar Mencl, Kenneth R Pugh, Pawel Skudlarski, John H Krystal.   

Abstract

BACKGROUND: Nicotine in tobacco smoke can improve functioning in multiple cognitive domains. High rates of smoking among schizophrenic patients may reflect an effort to remediate cognitive dysfunction. Our primary aim was to determine whether nicotine improves cognitive function by facilitating activation of brain regions mediating task performance or by facilitating functional connectivity.
METHODS: Thirteen smokers with schizophrenia and 13 smokers with no mental illness were withdrawn from tobacco and underwent functional magnetic resonance imaging (fMRI) scanning twice, once after placement of a placebo patch and once after placement of a nicotine patch. During scanning, subjects performed an n-back task with two levels of working memory load and of selective attention load.
RESULTS: During the most difficult (dichotic 2-back) task condition, nicotine improved performance of schizophrenic subjects and worsened performance of control subjects. Nicotine also enhanced activation of a network of regions, including anterior cingulate cortex and bilateral thalamus, and modulated thalamocortical functional connectivity to a greater degree in schizophrenic than in control subjects during dichotic 2-back task performance.
CONCLUSIONS: In tasks that tax working memory and selective attention, nicotine may improve performance in schizophrenia patients by enhancing activation of and functional connectivity between brain regions that mediate task performance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15050867     DOI: 10.1016/j.biopsych.2003.12.023

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  83 in total

1.  Variation in the nicotinic acetylcholine receptor gene cluster CHRNA5-CHRNA3-CHRNB4 and its interaction with recent tobacco use influence cognitive flexibility.

Authors:  Huiping Zhang; Henry R Kranzler; James Poling; Joel Gelernter
Journal:  Neuropsychopharmacology       Date:  2010-07-14       Impact factor: 7.853

Review 2.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

3.  Chronic smoking, but not acute nicotine administration, modulates neural correlates of working memory.

Authors:  Matthew T Sutherland; Thomas J Ross; Diaá M Shakleya; Marilyn A Huestis; Elliot A Stein
Journal:  Psychopharmacology (Berl)       Date:  2010-09-23       Impact factor: 4.530

4.  Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure.

Authors:  Samantha L Rushforth; Thomas Steckler; Mohammed Shoaib
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

5.  The nicotinergic receptor as a target for cognitive enhancement in schizophrenia: barking up the wrong tree?

Authors:  C Quisenaerts; M Morrens; W Hulstijn; E de Bruijn; M Timmers; J Streffer; J De la Asuncion; G Dumont; B Sabbe
Journal:  Psychopharmacology (Berl)       Date:  2014-02       Impact factor: 4.530

Review 6.  Nicotinic modulation of neuronal networks: from receptors to cognition.

Authors:  Huibert D Mansvelder; Karlijn I van Aerde; Jonathan J Couey; Arjen B Brussaard
Journal:  Psychopharmacology (Berl)       Date:  2005-07-02       Impact factor: 4.530

7.  Brain activity in cigarette smokers performing a working memory task: effect of smoking abstinence.

Authors:  Jiansong Xu; Adrianna Mendrek; Mark S Cohen; John Monterosso; Paul Rodriguez; Sara L Simon; Arthur Brody; Murray Jarvik; Catherine P Domier; Richard Olmstead; Monique Ernst; Edythe D London
Journal:  Biol Psychiatry       Date:  2005-07-15       Impact factor: 13.382

Review 8.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 9.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

Review 10.  Tobacco use among individuals with schizophrenia: what role has the tobacco industry played?

Authors:  Judith J Prochaska; Sharon M Hall; Lisa A Bero
Journal:  Schizophr Bull       Date:  2007-11-05       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.